Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
From Biopsy to Better Decisions: Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Learn how patient-derived organoids predict treatment response in metastatic colorectal cancer and explore findings from the OPTIC study on drug sensitivity and clinical outcomes.
Beyond Checkpoints: Strategic Use of CDX Models in Emerging IO Therapies
Learn how enhanced CDX models with humanized immune systems improve preclinical-to-clinical success in emerging immuno-oncology therapies.
Industry Insights with Henry Zhu and BPS Bioscience
Henry Zhu, CEO of BPS Bioscience, reflects on 20 years of growth, innovation, and the company’s role in advancing drug discovery research.
Advances in Preclinical Research using Human Co-culture Models: Applications in Immunology, Infectious Disease, and Oncology
Join Dr. Ethan Shelkey as he discusses human primary co-culture models with immune cells that are used in infectious disease studies and cancer therapeutic testing.
Cell-Based Assays for Immuno-oncology
Join Lonza scientist Ethan Shelkey as he explores how cell-based assays can assess immune activation and support immunotherapy development.
CAR Finder – A Platform for Rapid CAR T Cell Screening
Dr. Sandy Tretbar introduces CAR Finder Technology and shares practical strategies to improve mRNA-based CAR T cell screening and selection.
Integrating Functionalized Multi-omics in Oncology Drug Discovery
Discover how cutting-edge multi-omics approaches and Generative AI are reshaping oncology drug discovery.
Discovery and Engineering of High-Affinity Soluble T Cell Receptors via a High-Throughput Yeast-Based Platform
Join Dr. Garrett Rappazzo as he presents his team’s research on the discovery and engineering of soluble T cell receptors for peptide-HLA targeting therapeutics.
Reprogramming the Brain Tumor Microenvironment to Enhance Anti-Tumor Immunity
This Q&A report covers essential topics in reprogramming the brain tumor microenvironment, including macrophage roles, cytokine expression, and approaches to overcoming tumor immunosuppression.
Unraveling Immunotherapy Resistance in Advanced Melanoma: Novel Insights from Longitudinal Spatial Multiomics Studies
Explore immunotherapy resistance in melanoma with Dr. Camelia Quek through advanced spatial multiomics and single-cell analysis insights.
Reprogramming the Brain Tumor Microenvironment to Enhance Anti-Tumor Immunity
Join us to learn how recent discoveries about the brain tumor microenvironment can drive new therapeutic strategies to overcome tumor immunosuppression.
#ExpertAnswers: Lorcan Sherry and Aditya Pratapa on Analyzing Multiplex Immunofluorescence Images
Dr. Lorcan Sherry and Dr. Aditya Pratapa answer questions from a recent webinar where they present a novel workflow for analyzing multiplex immunofluorescence images.
#ExpertAnswers: Arutha Kulasinghe on Single-Cell Spatial Phenotyping for Biomarker Discovery
Dr. Arutha Kulasinghe discusses application of single-cell spatial phenotyping for characterizing the tumor microenvironment.
A Ready-to-Analyze High-Plex Spatial Signature Development Workflow for Cancer Immunotherapy
In this webinar, Aditya Pratapa and Lorcan Sherry present a new workflow for analyzing multiplex immunoflurescence images.
Unlocking Spatial Insights: Accelerate Discoveries 70% Faster with SignalStar™ Multiplex IHC
Join us to learn how to accelerate spatial biology discoveries by 70% with optimized, ready-to-go panels using SignalStar™ Multiplex IHC.
Spatial Phenotyping: A Revolutionary Approach to Biomarker Discovery for Cancer Immunotherapy
Dr. Arutha Kulasinghe discusses the potential of single-cell spatial phenotyping in biomarker analysis and how it can be used to characterize tumor microenvironments.
#ExpertAnswers: Nataliia Beztsinna and Marten Hornsveld on Pre-Clinical Immuno-Oncology
Nataliia Beztsinna and Marten Hornsveld describe how the tumor microenvironment modulates clinical responses and how patient-derived ex vivo and engineered in vitro models can be used for pre-clinical immuno-oncology testing.
Cancer Immunotherapy: Viruses, Vaccines, and other Immuno-Oncology Treatments
In this blog post, current cancer immunotherapy treatments are discussed, as well as some future directions for this rapidly developing field.
Industry Insights with Crown Bioscience: Analyzing the Suppressive TME in In Vitro Based Assays
Nataliia Beztsinna and Marten Hornsveld from Crown Bioscience talk about native and reconstituted TME assays, how they can help in the preparation for clinical trials, and what kinds of therapies in development would benefit the most from this kind of testing.
Industry Insights with Crown Bioscience: Targeting T Cells Within the Cancer-Immunity Cycle
In this episode of Industry Insights, Saskia De Man, PhD, Marrit Putker, PhD, and Pirouz Daftarian, PhD, from Crown Bioscience discuss assays and methods for evaluating T cell therapeutics, including organoids, co-cultures, and high content imaging.
Industry Insights with Crown Bioscience: In Vitro Technologies for Studying the Cancer-Immunity Cycle
In this episode of Industry Insights, Rajendra Kumari, PhD, and Gera Goverse, PhD, from Crown Bioscience answer questions about in vivo, in vitro, and ex vivo technologies and methods that can be used for immuno-oncology research along each step of the cancer-immunity cycle.
The Cancer-Immunity Cycle: Methods, Challenges, and Opportunities
In this series, experts provide an overview of technologies, techniques, challenges, and emerging research questions along each step of the cancer immunity cycle.
Analyzing the Suppressive TME in in Vitro Based Assays
Experts describe suppressive tumor immune microenvironment compartments and patient-derived tissue technologies capable of recapitulating the TME for clinically-relevant studies.
